

NUCLEOSIDES, XXVI<sup>1)</sup>.

AN ALTERNATE SYNTHETIC APPROACH TO GOUGEROTIN

Frieder W. Lichtenthaler, Tetsuo Morino, Wolfgang Winterfeldt  
and Yuzuru Sanemitsu


Institut für Organische Chemie, Technische Hochschule Darmstadt  
D-61 Darmstadt, Germany

(Received in UK 30th June, 1975; accepted for publication 29th August, 1975)

Gougerotin, an aminoacyl-aminohexosyl-cytosine antibiotic <sup>2)</sup> elaborated by various streptomycetes <sup>3)</sup>, has been shown to possess versatile antibacterial <sup>4)</sup>, acaricidal <sup>5)</sup>, anti-mycoplasma <sup>4b, 6)</sup> and antiviral <sup>7)</sup> activities, of which at least the former are due to interference with protein biosynthesis at the peptide chain elongation stage <sup>8)</sup>. Its correct structure (13) has only gradually evolved <sup>9)</sup> requiring two revisions <sup>9b, d)</sup> before being finalized by partial <sup>9a-g)</sup> and a first, 17 step total synthesis from methyl  $\alpha$ -D-galactoside (1) <sup>9h)</sup>. Our approach to the synthesis of gougerotin comprises a total of 13 steps from 1, based on a rather different series of reactions, the salient features being the catalytic oxidation of methyl 4-azido-4-deoxy- $\alpha$ -D-glucoside (2) to the uronic acid, its subsequent acetolysis (3  $\rightarrow$  4) <sup>10)</sup>, the stannic chloride catalyzed glycosidation with bis-trimethylsilyl-N-acetyl-cytosine (4  $\rightarrow$  5) <sup>11)</sup> and the direct introduction of the peptide portion (7  $\rightarrow$  11) by coupling with BOC-blocked sarcosyl-D-serine.

Catalytic oxidation of the primary hydroxyl group in 2, accessible from 1 in four steps in high overall yield (43 % <sup>10a, 12)</sup>, was readily accomplished by air over platinum black <sup>13)</sup> to give on esterification with diazomethane the known <sup>15)</sup> azidouronate 3 in 64 % yield. Treatment of 3 with acetic anhydride containing 2 % conc. sulfuric acid for 12 h at ambient temperature afforded, on elution from a silica gel column <sup>16a)</sup> to remove slower moving impurities, a 59 % yield of 4 as a syrup <sup>17)</sup>, comprising an approximate 1 : 3  $\alpha/\beta$ -mixture on the basis of pmr data (CDCl<sub>3</sub>):  $\delta$  5.63 (7 Hz-d, 0.3 H, H-1e) and 6.34 (3 Hz-d, 0.7 H, H-1a). When reacted in dichloroethane with N<sup>4</sup>-acetyl-bis(trimethylsilyl)-cytosine in the presence of stannic chloride (12 h, 60 °), the highly crystalline azido-nucleoside 5 <sup>17)</sup> was obtained in 67 % yield; needles, mp 225 - 227 ° effervesc.,  $[\alpha]_D^{22} + 38^\circ$  (c 0.4, CHCl<sub>3</sub>); relevant pmr peaks (CDCl<sub>3</sub>) at  $\delta$  1.95 and 2.12 (two 3H-s, 2' - and 3' -OAc), 2.26 (3H-s, N-Ac), 3.85 (3H-s, OMe), 6.15 (1H-d, J=9 Hz, H-1'), 7.45 and 7.67 (two 1H-d, J=7 Hz, H-5 and H-6). De-O-acetylation with methanolic sodium methoxide to 6, isolated as the monohydrochloride [mp 189 - 190 °,  $[\alpha]_D^{22} + 39^\circ$

(c 0.5, MeOH), 85 % yield], and subsequent hydrogenation over 10 % Pd/C in aqueous methanol containing hydrochloric acid gave 7 in form of the crystalline dihydrochloride monohydrate (87 % yield), identical by mp (220 - 225° dec), uv and ir data with the product prepared<sup>18)</sup> by acid hydrolysis of gougerotin and subsequent esterification.



For attachment of the dipeptide unit, N-t-butoxycarbonyl-sarcosyl-D-serine (9) [syrup,  $[\alpha]_{\text{D}}^{25} - 4^\circ$  (c 3, MeOH)] was used, readily accessible from its methyl ester<sup>19)</sup> in 79 % yield by alkaline hydrolysis (N NaOH/methanol, 0.5 h, 25°) and purification via a cellulose column<sup>16b)</sup> Coupling of 7 with 2 equiv. each of 9, triethylamine and dicyclohexylcarbodiimide (DCC) in methanol-acetonitrile followed by brief treatment with a strongly basic ion exchange resin (Merck III) to remove N, N' -diacylated product and subsequent column chromatography on silica gel<sup>16c)</sup> afforded the desired dipeptidyl nucleoside 11 in 56 % yield: monohydrate of mp

175 - 178<sup>o</sup>;  $[\alpha]_D^{26} + 39^o$  (c 1, H<sub>2</sub>O); uv (in 0.1 N H<sub>2</sub>SO<sub>4</sub>)  $\lambda_{max}$  276 nm; (in water)  $\lambda_{max}$  266; (in 0.1 N NaOH)  $\lambda_{max}$  268; relevant pmr peaks (DMSO-d<sub>6</sub>)  $\delta$  7.60 and 5.81 (two 7 Hz-d, H-6 and H-5), 5.57 (8 Hz-d, H-1'), 2.80 (3H-s, N-CH<sub>3</sub>), 1.40 (9H-s, BOC). In an alternate procedure, 7 was converted into 11 in a 51 % overall yield by DCC-coupling with N-benzyloxycarbonyl-D-serine (Z-D-Ser)<sup>9h</sup>, hydrogenolysis, and reaction of the resulting seryl-nucleoside 8 — readily isolated as the stable dihydrochloride, mp 225 - 230<sup>o</sup> (dec),  $[\alpha]_D^{25} + 4, 2^o$  (c 1, MeOH), yield 74 % from 7 — with N-t-butoxycarbonyl-sarcosine (BOC-Sar) by DCC(triethylamine in acetonitrile/methanol).

The final two steps were performed simply by exposure of 11 to methanolic ammonia (4 h, 25<sup>o</sup>) to give BOC-gougerotin 12 [mp 213 - 215<sup>o</sup> (dec),  $[\alpha]_D^{25} + 52^o$  (c 0.5, H<sub>2</sub>O), 78 % yield] and subsequent removal of the protecting group by treatment with trifluoroacetic acid (0.5 h, 25<sup>o</sup>). Gougerotin was isolated by passing through a small column of a strongly basic ion exchanger (Merck III) and recrystallization from methanol as colorless, needle-shaped crystals in 84 % yield.

The synthetic product was identical with natural gougerotin<sup>20</sup> by thin layer chromatographic<sup>1)</sup> ir, rotational and pmr<sup>1)</sup> comparison. In addition, the inhibitory activities on protein biosynthesis, as evaluated with the 70S promoted AcLeu-transfer from CACCA-LeuAc to puromycin<sup>21)</sup>, were also identical for synthetic and *S. gougerotii* derived 13, the apparent inhibition constant  $K_i'$  being 5.0  $\mu$ M. In the two gougerotin analogs 8 and 10<sup>22)</sup>, however, the inhibitory activities are reduced by factors of 252 and 63 as evidenced by  $K_i'$  - values of 1260 (8) and 317  $\mu$ M (10), stressing the importance of the sarcosyl portion in the antibiotic for full biological activity.

Acknowledgements: The support of this work by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie is gratefully acknowledged.

---

#### References and Notes

- (1) Part XXV: F. W. Lichtenthaler, T. Morino, and H. M. Menzel, *Tetrahedron Lett.*, 665 (1975).
- (2) (a) J. Černá, I. Rychlík, and F. W. Lichtenthaler, *Fed. Eur. Biochem. Soc. Lett.*, 30, 147 (1973). (b) F. W. Lichtenthaler and G. Trummlitz, *ibid.*, 38, 237 (1974).
- (3) Its isolation has been recorded from *Streptomyces gougerotii*<sup>4a)</sup>, from *Streptomyces S-154*<sup>4b)</sup>, from *Streptomyces SF-1238*, genealogically close to *S. toyocaensis*<sup>4c)</sup>, and from *S. toyocaensis* var. *aspiculamycticus*<sup>4d)</sup>. Since the antibiotic elaborated by the latter species, i.e. aspiculamyacin, has been shown to be identical with gougerotin<sup>1)</sup>, the designation *Streptomyces toyocaensis* var. *gougerotii* for this strain appears to be more appropriate.
- (4) (a) T. Kanzaki, E. Higashide, H. Yamamoto, H. Shibata, K. Nakazawa, H. Iwasaki, T. Takewaka, and A. Miyake, *J. Antibiot. (Tokyo)*, 15, 93 (1962). (b) T. Ikeuchi, F. Kitame, M. Kikuchi,

- and N. Ishida, ibid., 25, 548 (1972). (c) Personal communication (1973) from Dr. S. Inouye, Meiji Seika Co., Yokohama. (d) M. Arai, T. Haneishi, R. Enokita, and H. Kayamori, J. Antibiot. (Tokyo), 27, 329 (1974).
- (5) T. Haneishi, M. Arai, N. Kitano, and S. Yamamoto, J. Antibiot. (Tokyo), 27, 339 (1974).
- (6) F. Kondo, N. Kitano, H. Domon, M. Arai, and T. Haneishi, J. Antibiot. (Tokyo), 27, 529 (1974).
- (7) L. Thiry, J. Gen. Virol., 2, 143 (1968).
- (8) S. Pestka, Ann. Rev. Microbiol., 25, 520 (1971); D. Vazquez, Fed. Eur. Biochem. Soc. Lett., 40, s 63 (1974).
- (9) (a) H. Iwasaki, Yakugaku Zasshi, 82, 1358 - 1395 (1962), 11 papers. (b) J. J. Fox, Y. Kuwada, K. A. Watanabe, T. Ueda, and E. B. Whipple, Antimicrobial Agents Chemother., 1964, 518. (c) F. W. Lichtenthaler and P. Heidel, Angew. Chem., 80, 441 (1968). (d) J. J. Fox, Y. Kuwada, and K. A. Watanabe, Tetrahedron Lett., 6029 (1968). (e) H. Paulsen, K. Propp, and K. Heyns, ibid., 683 (1969). (f) K. A. Watanabe, M. P. Kotick, and J. J. Fox, J. Org. Chem., 35, 231 (1970). (g) F. W. Lichtenthaler, G. Trummlitz, G. Bambach, and I. Rychlik, Angew. Chem., 83, 331 (1971). (h) K. A. Watanabe, E. A. Falco, and J. J. Fox, J. Amer. Chem. Soc., 94, 3272 (1972).
- (10) Previous attempts to oxidize 2 with platinum black/oxygen and to acetylate 3 had been unsuccessful: (a) M. P. Kotick, R. S. Klein, K. A. Watanabe, and J. J. Fox, Carbohydr. Res., 11, 369 (1969). (b) K. A. Watanabe, I. M. Wempen, and J. J. Fox, ibid., 21, 148 (1972).
- (11) U. Niedballa and H. Vorbrüggen, Angew. Chem., 82, 449 (1970). F. W. Lichtenthaler, A. Heerd, and K. Strobel, Chemistry Lett. (Tokyo), 449 (1974).
- (12) E. J. Reist, R. R. Spencer, D. F. Calkins, B. R. Baker, and L. Goodman, J. Org. Chem., 30, 2312 (1965).
- (13) Using an Adams catalyst prepared from platinum oxide by hydrogenation in acetic acid and an EBM Tornado stirrer of 20,000 rpm for effective agitation, in large scale (15 - 20 g) adaptation of the procedure by Paulsen et al. <sup>14</sup>. Use of oxygen instead of air did not appreciably shorten reaction time (15 - 24 h at 30°C).
- (14) H. Paulsen, W. Kobernik, and E. Autschbach, Chem. Ber., 105, 1524 (1972).
- (15) The data obtained [mp 82 - 83°C and  $[\alpha]_D^{25} + 166^\circ$  (c 0.8, CHCl<sub>3</sub>)] correspond well with those reported by Fox et al. <sup>10a</sup>, yet are at variance with others <sup>14</sup>.
- (16) Eluants used: cyclohexane-ethyl acetate 3 : 1 (a), ethyl acetate-methanol-water 10 : 2 : 1 (b) and 5 : 2 : 1 (c).
- (17) Satisfactory pmr and ir spectra and analytical data (exact mass or elemental analysis) have been obtained for all new substances reported herein.
- (18) H. Iwasaki, Yakugaku Zasshi, 82, 1387 (1962).
- (19) F. W. Lichtenthaler, G. Trummlitz, and P. Emig, Tetrahedron Lett., 2061 (1970).
- (20) A sample, commercially available from Calbiochem. USA, was used for comparison.
- (21) (a) One of the most sensitive model systems for evaluating interference with peptide chain elongation; cf. lit. <sup>2a</sup> for specification. (b) We are indebted to Dr. H. M. Menzel of this laboratory for the biological evaluations.
- (22) Prepared by treatment of 8. HCl with methanolic ammonia as a monohydrate, mp 243 - 246°C (dec),  $[\alpha]_D^{25} + 48^\circ$  (c 0.3, H<sub>2</sub>O).